PubMed Health⌕ Search

Biomedical subjects

A Ruibal

Publications and source records attributed to A Ruibal.

At least 19 recordsLinked to original sources

Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study.

Estrogens, and to a lesser extent progesterones, influence the proliferation, differentiation and physiology of breast tissue as well as the development and progression of breast cancer. Genetic variants in the steroid hormone receptor genes ESR1 and PGR (belonging to the nuclear receptor superfamily) could therefore modify sporadic breast cancer susceptibility. Two studies have shown a protective effect associated with variants in ESR1 in 2 distinct populations. We studied 4 single nucleotide polymorphisms (SNPs) in ESR1 and 4 in PGR in 550 consecutive and unrelated sporadic Spanish breast cancer patients and 564 healthy Spanish controls. We observed a dominant protective effect for the S10S variant in ESR1, with an estimated odds ratio (OR) of 0.75 (95% CI = 0.58-0.97; p = 0.03) although functional studies did not show changes in the RNA stability. A small subset of individuals carried a haplotype combination that corroborates this protection. No other SNP considered in either gene was found to be associated with sporadic breast cancer. Our results obtained in a European population confirm the protective role of the S10S variant in ESR1, previously reported in an Asian and a European-American population.

Adult↗

[Preoperative lymphoscintigraphy to identify the sentinel lymph node in breast cancer].

INTRODUCTION: The preoperative lymphoscintigraphy to the Sentinel Node Biopsy (SNB) can reproduce the lymphatic drainage of the tumour in breast cancer. OBJECTIVES: To establish the pattern of lymphatic drainage of the mammary tumors by means of isotopic lymphoscintigraphy and determine the factors that could influence the negativity of the scintigraphy. METHODS: 121 patients with breast cancer who were going to undergo mammary surgery were studied with SNB. One day before the operation, 37 MBq 99mTc-colloidal sulphide colloid in a volume of 2 ml was injected in peritumoral tissue. Mammary lymphoscintigraphies were performed at 30 minutes and 18 hours P.I., in ANT and OA projections of the corresponding chest. After, the clinical-biological parameters and their influence on the result of the lymphoscintigraphy were analyzed. RESULTS: The scintigraphy were positive in 85 % of the patients. The axillary chain was observed in 97 % and the internal mammary chain in 11 %. The factors associated to the absence of visualization of the sentinel node were: older than 50 years (94 %), menopause (89 %), tumoral size > or = 2 cm (67 %), axillary metastases (67 %), the overexpression of C-erbB-2 oncoprotein (44 %) and proliferative activity > 10 % (67 %). CONCLUSIONS: The peritumoral injection of the radiocolloid establishes the lymphatic drainage pattern in the patients with breast cancer. Its absence of visualization can be associated to circumstances like: age > or = 50 years, menopause, tumoral size > or = 2 cm, axillary metastases, tumoral overexpression of the C-erbB-2 oncoprotein and high proliferative activity of the mammary tumor.

Adult↗

Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.

OBJECTIVE: To compare renal handling of uric acid in patients with primary gout with that of a control group. METHODS: A case-control study of 100 patients with primary gout and 72 healthy controls was undertaken. Creatinine clearance, uric acid clearance, 24-hour uric acid urinary excretion, fractional excretion of uric acid, excretion of uric acid per volume of glomerular filtration, urinary uric acid to creatinine ratio, and glomerular uric acid filtered load were calculated using 24-hour urine samples. After treatment with allopurinol to achieve similar glomerular filtered load of uric acid, patients were again compared with controls. RESULTS: Patients with gout showed lower uric acid clearance, fractional excretion of uric acid, excretion of uric acid per volume of glomerular filtration, and urinary uric acid to creatinine ratio than controls at baseline, when patients showed hyperuricemia. Although the glomerular uric acid filtered load was much higher in patients with gout than controls, 24-hour uric acid excretion was not statistically different. After treatment with allopurinol, and achieving similar uric acid filtered loads, patients still showed lower figures than controls. When patients with 24-hour urinary uric acids levels >700 mg/day were compared with controls, they had lower uric acid clearance and fractional excretion of uric acid than controls, both at baseline and after achieving similar filtered loads with allopurinol therapy. CONCLUSIONS: Renal underexcretion is the main mechanism for the development of primary hyperuricemia in gout, but even patients showing apparent high 24-hour uric acid output show lower uric acid clearance than controls, indicating that relative, low-grade underexcretion of uric acid is at work.

Adult↗

[Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters].

INTRODUCTION: pS2 was first identified as an estrogen induced molecule in a breast cancer cell line, but its gene responds to several growth factors and oncogenic proteins. Its main clinical application lies in breast carcinomas, where it is a molecular marker to identify breast cancer patients who will respond to hormone therapy. This study was performed to evaluate the significance of the pS2 cytosolic levels in non small cell lung carcinomas classified according to different clinical and biological parameters. Likewise, the results obtained were correlated with those observed in normal tissues. MATERIAL AND METHODS: The study group included 154 non small cell lung carcinomas (59 adenocarcinomas and 95 squamous carcinomas) and 54 normal lung samples. Cathepsin D, pS2, neuron specific enolase (NSE) and CA125 cytosolic concentrations were determined, as well as those of epidermal growth factor receptor (EGFR), erbB2 protein, CD44s, CD44v5 and CD44v6 on cell surface membranes. Likewise, clinical stage, histological grade, ploidy and cellular S-phase fraction were also considered as variables of the study. RESULTS: We observed cytosolic pS2 values greater than 1 ng/mg protein (positive cutoff) in 18/59 adenocarcinomas and in 10/95 squamous carcinomas (p:0.00177). In adenocarcinomas, pS2 positivity was not correlated with any clinical and biological parameters, but positive cases had lower EGFR (p:0.03770) concentrations and higher CA125 (p:0.01902) levels. In squamous carcinomas, pS2 positivity was associated with lower EGFR (p:0.02270) levels and higher erbB2 protein (p:0,00563) concentrations. CONCLUSIONS: Our results led us to suggest the following: 1) cytosolic pS2 concentrations are higher in tumoral than in normal samples; 2) adenoarcinomas had higher levels than squamous lung carcinomas; 3) in adenocarcinomas, positivity for pS2 is associated with lower EGFR levels and higher CA125 concentrations suggesting a worse outcome, and 4) in squamous lung tumors, positivity for pS2 was associated with lower EGFR and higher erbB2 oncoprotein concentrations, it not being possible to establish its clinical significance, although it may be correlated with a poor prognosis.

Adenocarcinoma↗

PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.

OBJECTIVES: The uPA-PAI system has been shown to play a role in the development of a more aggressive tumor phenotype. The PAI-1 promoter 4G/5G polymorphism, furthermore, regulates free plasma PAI-1 levels in patients with myocardial infarction. Our aim was to verify if the different polymorphisms in the PAI-1 promoter are also associated with alterations in the intracellular accumulation of uPA-PAI complexes in human breast cancer. METHODS: Accumulation of uPA-PAI complexes inside the tumor cells was determined by means of immunohistochemistry, as previously described by our own group, and two extremely different sets of tumors were chosen, one of them with strong uPA-PAI complex reactivity inside more than 50% of tumor cells, the other with no demonstrable reactivity at all. Finally, the 4G/5G polymorphism of the PAI-1 promoter was studied in all of them by means of DNA extraction, PCR amplification of the PAI promoter sequence, and restriction polymorphism typing. RESULTS: Absence of intracellular uPA-PAI complex accumulation was significantly associated with the prevalence of the 4G allele and, conversely, the presence of uPA-PAI complexes inside the tumor cells was significantly associated with 5G/5G homozygosity (logistic regression, p = 0.0128). Furthermore, none of the 7 5G/5G homozygous tumors showed histological grade 3, as did 6/21 tumors in the group where the 4G allele was present. In spite of the low case number, this association of the 5G/5G polymorphism with a less aggressive phenotype almost reached statistical significance (Spearman's correlation test, p = 0.118). CONCLUSIONS: The 4G/5G polymorphism of the PAI-1 promoter seems indeed to be associated with different rates of uPA-PAI complex internalization by breast cancer cells. Complex accumulation inside the tumor cells is significantly related to 5G/5G homozygosity, and this shows a trend towards an association with a less aggressive, better-differentiated tumor phenotype.

Breast Neoplasms↗

[Secreted tumor markers and breast cancer].

The tumor secretion markers used most in the daily practice are reviewed, emphasizing the physiological aspects having great practical usefulness. Likewise, the possible value of other recently described substances which could be introduced into the daily practice in the near future is explained.

Antigens, Neoplasm↗

[Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].

INTRODUCTION: The tissue-specific polypeptide antigen (TPS) is an epitope of the tissue polypeptide antigen (TPA) which is defined by the M3 monoclonal antibody and is related to cytokeratin 18. Several groups have demonstrated its value as a useful parameter in the follow-up of some tumors. This work has aimed to study the TPS cytosolic levels in infiltrating ductal carcinomas of the breast (IDC) and their possible correlations with other clinical-biological parameters. PATIENTS AND METHODS: The TPS was determined by means of an immunoradiometric assay (Beki Diagnostics. Sweden). Other parameters included in the study were the estrogen receptors (ER), progesterone receptors (PR), pS2, cathepsin D, tissue-type plasminogen activator (t-PA), tumor size, axillary lymph node involvement, distant metastases, histological grade, ploidy and S-phase. RESULTS: The TPS cytosolic levels ranged from 1.8 to 606.3 KU/mg prt. (median 110.2) and had a significant correlation with the ER (r: 0.721), PR (r: 0.287), cathepsin D (r: 0.550) and t-PA (r:0.436). The TPS positive (> 110.2 KU/mg prt.) carcinomas had higher levels of ER (p: 0.001), PR (p: 0.021), pS2 (p: 0.058), cathepsin D (p: 0.000) and t-PA (p: 0.053) than the TPS negative tumors. When the IDC were classified according to S-phase values, we observed that the positive cases (S-phase > 8.1%, which represents the median value of all carcinomas) had lower levels of TPS (p: 0.046) than the negative tumors. Likewise, the GoG1 cellular fraction correlated positively and significantly with the TPS cytosolic levels (p: 0.000). CONCLUSIONS: Based on our results, we suggest that there is a positive correlation between the TPS cytosolic levels and hormone-dependence parameters, as well as an inverse correlation between these and the cellular proliferation parameters. Based on the above, we consider that it is worthwhile to carry out further studies on cytosolic TPS in order to investigate its possible value as a prognostic parameter in breast carcinomas.

Breast Neoplasms↗

[Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].

INTRODUCTION: There are several discrepancies in the literature concerning breast cancer behavior in elderly women. For this reason, we decided to study the possible clinical-biological differences between infiltrating ductal breast carcinomas in women older than 60 and those between 41 and 60 years old. PATIENTS AND METHODS: The study group included 161 women with infiltrating ductal carcinomas of the breast, 90 of whom were women over 60 years and 71 whose ages ranged from 41 to 60 years old. Estrogen receptors (ER), progesterone receptors (PR), pS2, cathepsin D, tissue-type plasminogen activator (t-PA) and hyaluronic acid (HA) cytosolic concentrations were analyzed in addition to those of the epidermal growth factor receptor (EGFR), HA and erbB2/neuoncoprotein in cell surfaces. Size, axillary lymph node involvement, distant metastases, histological grade, ploidy and cellular S-phase fraction were also considered as study variables. RESULTS: Infiltrating ductal carcinomas of the breast in women over 60 had lower pS2 concentrations (p: 0.0367), cell surface (p: 0.021) and cytosolic hyaluronic acid (p: 0.0019) levels than those of women whose ages ranged from 41 to 60 years old. Furthermore, the former had higher S-phase values (p: 0.0345) and percentage of cases with S-phase >7% (p: 0.0483). CONCLUSIONS: The results obtained (higher cellular proliferation and lower pS2, cell surface and cytosolic hyaluronic acid concentrations) suggest that the infiltrating ductal carcinomas of the breast in women older than 60 could have a worse behavior, as has been suggested by other authors, even though further studies with more patients would be needed in order to observe if these biological differences still persist.

Adult↗

[Carcinoembryonic antigen levels (CEA) in 67 breast secretions caused by mammary duct ectasia].

In order to study the behavior of the carcinoembryonic antigen (CAE), we assayed the concentrations of CEA in 67 nipple discharges of women with duct ectasia of the breast by means of a fluoroimmunoassay (EG & G. Wallac. Finland). The CEA concentrations ranged from 0.1 to 854 ng/ml (median 38.7), these being higher (p: 0.065) in the luteal phase (34 cases; range: 5.0-854, median 61.7) than in follicular phase of the menstrual cycle (29 cases; range: 0.1-452; median 30.5). Concentrations greater than 400 ng/ml were observed in two cases (2.98%) and none of the cases showed CEA values higher than 1000 ng/ml. Our results suggest that nipple discharges by ductal ectasia of the breast can be associated with increases in CEA, which can be explained by its own physiopathology, although it rarely (3%) exceeded 400 ng/ml.

Body Fluids↗

[Electrophoretic patterns of lactate dehydrogenase isoenzymes in fluid from 261 benign breast cysts].

BACKGROUND: Some groups have described the presence of lactate dehydrogenase (LDH) and certain isoenzymes in breast cyst fluids, but their clinical usefulness is unknown. We have studied the behavior of LDH isoenzymes in benign breast cysts fluids with the aim of understand their clinical meaning. SUBJECTS AND METHOD: The study group included 261 benign breast cyst fluids classified, according to the Na+ / K+ ratio, as follows: type I (Na+ / K+ >/= 3): 188, and type II (Na+ / K+ > 3):73. The electrophoretic LDG isoenzymes analysis was carried out with the PARAGON system and the Appaise Junior densitometer from Beckman Instruments (U.S.A.). RESULTS: The results were as follows: a) type II was more frequently associated with the presence of LDH than type I breast cyst fluids (41/73 vs 9/188; p < 0.0001) and b) the LDH5 isoenzyme positivity was higher in type II than in type I breast cysts fluids (29/41 vs 4/188; p < 0.001) also and it correlated with higher pH, C1, carcinoembryonic antigen and Na+ / K+ ratio values. CONCLUSIONS: Our results led us to consider that LDH and LDH5 isoenzyme positivity is associated with type II breast cyst fluids, suggesting that it does not reflect a higher transformation risk, but rather that is a consequence of cyst evolution and of its lining wall.

Electrophoresis↗

[The cytosolic hyaluronic acid level defines several clinico-biological properties of CD44v5-positive infiltrating ductal carcinoma of the breast].

BACKGROUND: The hyaluronic acid (HA) is a ligand of CD44 adhesion molecule. In this work, we study if the cytosolic level of this proteoglycan can modulate certain clinical-biological properties at CD44v5-positive infiltrating ductal carcinomas (IDC) of the breast. PATIENTS AND METHODS: We have assayed, by a radioligand method, the cytosolic level of hyaluronic acid in 127 IDC. Likewise, cytosolic levels of estrogen receptors (ER), progesterone receptors (PR), pS2, cathepsin D and tissue.-type plasminogen activators (t-PA) have been dossified, as well as those of epidermal growth factor receptor (EGFR) at cell surfaces. The menopausal status, tumor size, axillary lymph node involvement, histological grade, ploidy and S-phase have also been taken into account. RESULTS: HA positive (> 4800 ng/mg prt., which represents the median value obtained with 252 tumors) carcinomas had higher levels of PR (p = 0.035) and t-PA (p = 0.000), whereas HA negative showed a higher frequency of a tumor size > 2 cm (p = 0.015), aneuploidy (p = 0.015) and S-phase > 14% (p = 0.019), as well as histological grade 3 which reached statistical significance (p = 0.062), all of which were indicators of a worse behaviour and evolution. CONCLUSIONS: Our results suggest that, as it also happens with that of the cell surface, cytosolic HA levels seems to modulate certain clinical-biological features of CD44v5-positive infiltrating ductal carcinomas of the breast. Likewise, they can help us to explain the discordant results described at the literature concerning its practical value when each of them are considered separately.

Adult↗

[Expression of the adhesion molecule CD44v6 in infiltrating ductal carcinomas of the breast is associated with hormone dependence. Our experience with 168 cases].

In order to investigate the possible hormone-dependence of CD44v6 in human breast cancer, we assayed the concentrations of this isoform in the membrane fraction of 168 invasive ductal carcinomas (IDC) and in 26 normal breast tissue samples, 18 fibradenomas (FAD), 3 fibrocystic disease specimens (FD), 7 mucinous carcinomas and 4 medullary carcinomas using the ELISA method. The results were compared with those of the estrogen (ER) and progesterone (PR) receptors, pS2, tissue type plasminogen activator (t-PA), cathepsin D, epidermal growth factor receptor (EGFR) and c-erbB2/neu oncoprotein concentrations. Menopausal status, size of the tumor in the cases of cancers, axillary lymph node involvement, histologic grade, ploidy, cellular synthesis phase, multifocality and multicentricity were also considered as variables. The cut-off value for CD44v6-positivity was set at 5 ng/mg prt. membrane protein content. 64/138 (38.1%) infiltrating ductal carcinomas scored positive. This was significantly higher than for the normal breast tissue (0/26; p: 0.0001), similar to that seen in the FAD (3/18), fibrocystic disease (0/3), infiltrating mucinous carcinomas (4/7) and lobular (3/15) and significantly lower than for the infiltrating medullary carcinomas (4/4; p: 0.027). There were no significant differences with the other groups of tissues studied. Furthermore, CD44v6-positive IDC showed significantly higher concentrations of ER, PR and cathepsin D and lower (p: 0.051) concentrations of EGFR when compared to their CD44v6-negative counterparts. The significant coexpression of ER, PR and cathepsin D seems to indicate a possible role for hormonal regulation of CD44v6 expression while the role of pS2 and t-PA, estrogen related proteins, was very reduced.

Adenocarcinoma, Mucinous↗

[Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].

UNLABELLED: The pS2 protein is regulated by estrogens, but it can also be expressed in hormone independent breast carcincomas. We have carried out the present study in order to analyze the clinical-biological impact of pS2 positivity (>2 ng/mg prt.) in negative estrogen receptors (< 10 fmol/mg prt.) infiltrating ductal breast carcinomas (IDC). MATERIAL AND METHODS: 97 negative ER-IDC have been included in our study. We established the doses of the cytosol levels of pS2, progesterone receptors (PR), cathepsin D, tissue -type plasminogen activator (t-PA) and hyaluronic acid (HA), as well as the levels of HA, epidermal growth factor receptor (EGFR), CD44v5 and CD44v6 in cell surface membranes. We also considered the menopausal status, histological grade, ploidy, cellular synthesis phase, tumor size, axillary lymph node involvement and the existence of distant metastasis. The same results were obtained when the progesterone receptor status was also considered. RESULTS: ER-/pS2+ IDC presented higher (p <0,05) PR, t-PA and HA cytosol level, as well as lower EGFR concentrations, S-phase > 7% and S-phase >14% and lower N+>10 percentages and aneuploidy. They were also more frequently CD44v6+. The same results were observed when the positivity of the progesterone receptors was considered. CONCLUSIONS: The above results lead us to consider that the positivity for pS2 in ER- IDC is associated with hormone-dependent parameters, good differentiation and lower cellular proliferation, which can explain a better clinical outcome.

Biomarkers, Tumor↗